




版权说明:本文档由用户提供并上传,收益归属内容提供方,若内容存在侵权,请进行举报或认领
文档简介
山东省立医院肿瘤中心CenterofTumor,ShandongProvincialHospital
叶欣YeXin
yexintaian@
2015.8.15.福州.经皮微波/射频消融治疗早期周围型非小细胞肺癌临床研究进展Clinicalstudyonthepercutaneous
microwave/radiofrequencyablationof
peripheralearlystagenon-smallcelllungcancer肺癌微波/射频消融开展情况和目前规范指南
2000200420062008200920102011201220132014LIVER8.50012.00016.00038.000126.000250.000370,000460,000520,000642,000LUNG19003,00016,00056,000100,000210,000330,000431,000574,000KIDNEY1507001.50012.00042.00080.000130,000160,000192,000212,000BONE1207001.5008.00011.00030.00045,00056,00064,00082,000OTHERS1002001.00015.00019.00030.00070,000110,000182,000273,000TOTAL8,87114,50023,00089,000254,000490,000825,0001116,0001,389,0001,783,000欧美国家热消融治疗例数的估计Estimationof
thenumberofthermal
ablation
patientsinthe
EuropeanandAmerican
48硬膜外和鞘内止痛药2-6%2013;143(5)(Suppl):e278S–e313STheroleofablativetherapiesinthetreatmentofhigh-riskpatientswithstageINSCLCisevolving.RFablation,themoststudiedoftheablativemodalities,hasbeenusedeffectivelyinmedicallyinoperablepatientswithsmall(3cm)peripheralNSCLCthatareclinicalstageI.硬膜外和鞘内止痛药2-6%神经阻断、姑息手术1-5%硬膜外和鞘内止痛药2-6%(10)心肺功能等机体状况经评估无法接受手术的I期和Ⅱ期的NSCLC患者,可选择根治性放射治疗、射频消融治疗和药物治疗等。
PhilippeL,Pereira,MasalaSalvatore.StandardsofPractice:GuidelinesforThermalAblationofPrimaryandSecondaryLungTumors.Cardiovasc
Intervent
Radiol,2012,35:247-254.硬膜外和鞘内止痛药2-6%ThoracicCancer2015;6:112–121TranslLungCancerRes2015;4(3):310-321Radiology2014;273:241–260Energy-basedAblationThiscategoryincludesmodalitiesthatdestroyatumoreitherthroughthermal(heatorcold)ornonthermalmechanisms.Forthermaltherapies,energyis“applied.”Theterm“irradiationofenergy,”particularlyinregardtomicrowaveablation,isamisnomerandshouldthereforebeavoided.Thefollowingenergy-basedmodalitieshavebeendescribed.RFablation.—,Microwaveablation.—,Ultrasoundablation.—Laserablation.—,Cryoablation.Irreversibleelectroporation疗效观察和评价ClinicalEvaluationClinicalefficacyLocalefficacy,OverallsurvivalCT:contrast-enhancementT1W
enhancementMRI:
DWI(diffusion-weightedimaging)
ADC(apparentdiffusioncoefficient)
PET-CT:SUV硬膜外和鞘内止痛药2-6%CTFollow-upassessment*Disappearance*Cavitation*Fibrosis*Nodule*AtelectasisDisappearanceFibrosisNoduleAtelectasisCavitationDonC.Yoo,etal.AJR2011;197:334–3403months6months6months6months硬膜外和鞘内止痛药2-6%JournalofMedicalImagingandRadiationOncology••(2015)doi:10.1111/1754-9485.12330硬膜外和鞘内止痛药2-6%79-year-oldmalewithLUL24mmSCC.硬膜外和鞘内止痛药2-6%Semin
Intervent
Radiol2013;30:157–168硬膜外和鞘内止痛药2-6%硬膜外和鞘内止痛药2-6%1989–2003,101,844patientsinCaliforniastageI:mediansurvival13msoverallsurvivalforuntreatedpatientswithNSCLC,stageI-IV(n=22,954).5-yearsurvivalrateswerestageI:7%;stageII-IV:0%Chest.
2007Jul;132(1):193-9.硬膜外和鞘内止痛药2-6%2013;143(5)(Suppl):278S–313SBasedonsuchretrospectiveseriesofresectedstageIandstageIINSCLC,theprognosesforstageIandIINSCLC,expressedintermsof5-yearsurvivalrates,arecommonlyacceptedtobe60%to80%forstageIand30%to50%forstageIINSCLC.1-year,2-year,3-year,5-year(OSrates)
78%--100%,53%--86%,36%--88%,25%--61%.
1-year,2-year,3-year(cancer-specificsurvivalrates)89%--100%,92%--93%,59%--88%.Themediansurvivaltimerangedfrom29--67months.BioMedResearchInternational
2014;2014:152087Cancer2015;000:000-000.Theoverallsurvivalrate86.3%at1year69.8%at2years.Cardiovasc
Intervent
Radiol2015,38:160–166硬膜外和鞘内止痛药2-6%神经阻断、姑息手术1-5%PatientsMaxdiameterSD:3.0±0.9cm;Survivalrate:1y:69%,2y:54%,3y:49%EurJCardiothoracSurg.
2013
Apr;43(4):683-6.RFA,≤2cmcanbecompletedablatedin78-96%MWA≤5cmcanbecompletedablatedin95%Fornodules≤3cm,thesurvivalrateishigher:50%atfiveyears.Pulmonarymetastasis,lesionsare≤5cm.EurJCardiothorac
Surg.
2013
Apr;43(4):683-6.硬膜外和鞘内止痛药2-6%神经阻断、姑息手术1-5%JVasc
Interv
Radiol2014;25:1–9
Resectiongroup:90days,1year,and2years100%,88.3%,and75.8%Ablationgroup:98.6%,88.7%,and66.1%.硬膜外和鞘内止痛药2-6%JVasc
Interv
Radiol2013;24:476–482
硬膜外和鞘内止痛药2-6%
1-,2-,3-yOS:Surgery:100%,95%,83%RF:91%,73%,55%Themediancostpermonthlived
RF:$620.74Surgery:$1,195.92Conclusions:
Patientstreatedwithsurgeryshowedasignificantincreaseinsurvival;however,thosetreatedwithRFablationweresignificantlyolder.Forpatientswhoarenotsurgicalcandidates,RFablationprovidesanalternativetreatmentoptionatasignificantlylowercost.
硬膜外和鞘内止痛药2-6%LancetOncol
2015;16:630–37张玉蛟JoeYChang3yOS:96%:79%3yRFS:86%:80%硬膜外和鞘内止痛药2-6%JVasc
Interv
Radiol.2013Aug;24(8):1139-45
硬膜外和鞘内止痛药2-6%55.8%/3y,59%/3y,47%/5y,40%/5y,IntJClin
Oncol(2015)20:499–507RFA(47)SBRT(48)pdiameter
2.0
±
0.8
(0.6-3.9)2.1
±
0.9(0.8-4.7)
0.539localprogression9.6
%
7.0
%,0.7463-yearOS86.4
%,79.6
%0.738硬膜外和鞘内止痛药2-6%JThorac
Cardiovasc
Surg2013;145:692-99Respiration.2015;89(6):550-7116patientsstageINSCLCSublobarresection(n=42),Radiofrequencyablation(n=25)Radiotherapy(n=49)Conclusions:
OurstudysuggeststhatSLRwasassociatedwithahigherprimarytumorcontrolratecomparedtoRFAorRT.AlthoughtheOSswerenotdifferent.
Theseresultsshouldbeconfirmedinprospectivetrials.Theprobabilitiesof1-and2-yearOSwere94and85%fortheSLRpatients,86and74%forRFApatientsand93and69%fortheRTpatients,respectively.Respiration.2015;89(6):550-7
1-2-yearSLR:9485%RFA:8674%RT:9369%116patientsstageINSCLCSublobarresection(n=42),Radiofrequencyablation(n=25)Radiotherapy(n=49)JVasc
Interv
Radiol2014;25:333–3391-year,3-year,5-year(OS)
100%,96.4%,96.4%1-year,3-year,5-year(cancer-specificsurvival)100%,100%,100%,(33consecutivepatients,meanfollow-upof42months
)Cardiovasc
Intervent
Radiol(2015)38:409–4151-year,5-year,93.3%,93.3%,1-year,5-year,(cancer-specificsurvival)100%,100%,(16consecutivepatients,meanfollow-upof61.5months
)硬膜外和鞘内止痛药2-6%53monthsafterRFAFollow-up5yearsFollow-up30msFollow-up40ms硬膜外和鞘内止痛药2-6%JMedImagingRadiat
Oncol.2015Feb;59(1):82-90.
75-y,F.T1N0M0.PETscan5monthspost-conclusionofXRTshowsresiduallocaltumouravidity;MedianOS:62ms.4yr
controlrate:44.1%.Retreatedupto4times.Size(
>2cm).Numberof
metastases
(
≥3).SignificantlyassociatedwithOS.AnnalsofOncology26:987–991,2015Radiology.
2015Jun8:141153.[Epubaheadofprint]1-yearlocalprogressionrate:12.7%largevesselorabronchus:30.4%;No-largevesselorabronchus:0%;1-,2-,3-yearOS84.1%,79.2%,66.0%68.6%,34.3%,0%(uncontroll-extr-lung)我们的工作和经验Ourworkandexperience12ms24msM,67y,Largecellcarcinoma,
2.9cm硬膜外和鞘内止痛药2-6%神经阻断、姑息手术1-5%M,78y,Squamouscellcarcinoma,2.5cm硬膜外和鞘内止痛药2-6%神经阻断、姑息手术1-5%1月3月6月24月M,72y,Adenocarcinoma2.9cm硬膜外和鞘内止痛药2-6%Female:70‐year‐oldpatientwith5.0cm4.5cmrightlungcancer(squamous)a:Tumorlesion(arrow)seenonCTimmediatelypriortoMWA.b:Twomicrowaveantennapunctureintothelesion(arrow).c:AblatedlesionwithsurroundingGGOseenonrepeatCTscanimmediatelypost‐MWA.d:6msafterablation,lesionslightlyshrinking(arrow).e:12monthsafterablation.f:36msshowsa
温馨提示
- 1. 本站所有资源如无特殊说明,都需要本地电脑安装OFFICE2007和PDF阅读器。图纸软件为CAD,CAXA,PROE,UG,SolidWorks等.压缩文件请下载最新的WinRAR软件解压。
- 2. 本站的文档不包含任何第三方提供的附件图纸等,如果需要附件,请联系上传者。文件的所有权益归上传用户所有。
- 3. 本站RAR压缩包中若带图纸,网页内容里面会有图纸预览,若没有图纸预览就没有图纸。
- 4. 未经权益所有人同意不得将文件中的内容挪作商业或盈利用途。
- 5. 人人文库网仅提供信息存储空间,仅对用户上传内容的表现方式做保护处理,对用户上传分享的文档内容本身不做任何修改或编辑,并不能对任何下载内容负责。
- 6. 下载文件中如有侵权或不适当内容,请与我们联系,我们立即纠正。
- 7. 本站不保证下载资源的准确性、安全性和完整性, 同时也不承担用户因使用这些下载资源对自己和他人造成任何形式的伤害或损失。
最新文档
- 2025商场店铺租赁合同标准范本
- 2025工程分包合同标准范本
- 2025设备采购合同示范文本GF
- 2025商业银行保安服务合同
- 养殖鱼塘转租合同样本
- 材料采购议标方案范本
- 媒体产业品牌宣传方案计划
- 借贷合同 投资合同样本
- 出电子合同样本
- 农村房屋争议合同标准文本
- 2022新教材苏教版科学5五年级下册全册教学设计
- 干部履历表填写范本(中共中央组织部1999年)
- 2024年电力市场居间服务合同模板
- 铁路技规(全-上传)
- 《学术规范与论文写作》课程教学大纲(本科)
- 2024年海南省国有资本运营有限公司招聘笔试冲刺题(带答案解析)
- 大棚包工包料施工合同范本
- 2024年湖南省岳阳市岳阳楼区小升初数学试卷附答案解析
- 2024提高治疗前肿瘤TNM评估率工作方案(修改版)
- 2023年孕妇健康管理分析报告
- 2024年高考语文新课标1卷讲评+课件
评论
0/150
提交评论